Physician profile
Casey Colangelo
NPI 1821613191
$8,997.74
in general payments reported to CMS, 2019-2025
29 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $2,048 · 2023: $2,811 · 2024: $1,634 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,704 · Education: $103 · Travel and Lodging: $39.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,704.08 |
| Education | $102.99 |
| Travel and Lodging | $39.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,507.37 | 2022-2025 | |
| Lilly USA, LLC | $923.07 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $627.57 | 2021-2024 | |
| Janssen Biotech, INC. | $612.24 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $607.52 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $537.26 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $512.20 | 2022-2025 | Dupixent |
| Ucb, INC. | $476.02 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $446.42 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $361.43 | 2022-2024 | |
| Amgen INC. | $291.52 | 2022-2023 | Otezla |
| Leo Pharma INC. | $283.23 | 2022-2025 | Anzupgo, Adbry |
| Dermavant Sciences, INC. | $282.39 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $274.70 | 2023-2025 | |
| Organon LLC | $235.34 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $208.76 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Galderma Laboratories, L.P. | $201.88 | 2022-2025 | Aklief, Nemluvio, Epsolay |
| Pfizer INC. | $156.81 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.63 | 2022-2025 | Duobrii, Arazlo, Jublia |
| Almirall LLC | $83.95 | 2021-2025 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.90 | 2022-2024 | Spevigo |
| Epi Health, LLC | $65.94 | 2022 | |
| Verrica Pharmaceuticals INC. | $27.41 | 2023-2024 | Ycanth |
| Mallinckrodt Hospital Products INC. | $18.11 | 2025 | Acthar |
| Revance Therapeutics, INC. | $17.63 | 2025 | Daxxify |
| Kyowa Kirin, INC. | $16.43 | 2023 | Poteligeo |
| Mayne Pharma Commercial LLC | $13.87 | 2022 | |
| Strata Skin Sciences, INC. | $13.34 | 2024 | Xtrac |
| Biofrontera INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Colangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.